FDA Commissioner Marty Makary named Vinay Prasad as the next director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, overseeing the regulation of vaccines, gene therapies, and the blood supply, reported STAT, citing an email informing staff of the hiring. Prasad has sharply criticized the medical mainstream, including the FDA, in the past, noted STAT’s Lizzy Lawrence, Matthew Herper, and Jason Mast. In midday trading following the news, the SPDR S&P Biotech ETF (XBI) is down 5% to $78.26. Biotech stocks that could be impacted by the news include Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Moderna (MRNA), Novavax (NVAX) and Lexeo Therapeutics (LXEO).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- XNCR Upcoming Earnings Report: What to Expect?
- Xencor’s Promising Pipeline and Strategic Positioning Justify Buy Rating
- Xencor’s Promising Biotech Innovations and Strategic Growth Potential Justify Buy Rating
- Promising Outlook for Xencor’s XmAb942 Program Amidst Stock Decline
- Xencor’s Promising Developments in IBD Treatment Drive Buy Rating